The GLP-1 Effect: Market Penetration In the UK, 4.2 million adultsnearly 1 in 10had recently used a GLP-1 medication or expressed interest in doing so as of early 2025 Two in five overweight Britons (38%) express interest in using GLP-1s for weight loss when informed about the drugs Across Europe, the GLP-1 market is valued at 9.62 billion in 2025, with robust growth expected due to rising obesity and diabetes rates, improved access, and strong healthcare infrastructure in markets like Germany, France, and the UK Social acceptance is rising, and insurance coverage is likely to expand, further accelerating adoption
After a 4-week screening period, participants were randomly assigned, 1:1:1:1:1, to once-weekly 2.5 mg, 5 mg, 10 mg or 15 mg VK2735 or placebo for 13 weeks
If symptoms are severe, persistent, or worrying, that is a reason to check in with your provider rather than push through
It may result from Tirzepatides effects on the digestive system and changes in gut motility
